Actively Recruiting

Phase 1
Age: 18Years - 60Years
MALE
Healthy Volunteers
NCT07034183

A First-in-Human Study of PRD001

Led by PRD Therapeutics, Inc. · Updated on 2025-07-30

86

Participants Needed

1

Research Sites

49 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of PRD001 in healthy participants and to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of PRD001 in participants with borderline/mild hyper-LDL-cholesterolemia and mild fatty liver.

CONDITIONS

Official Title

A First-in-Human Study of PRD001

Who Can Participate

Age: 18Years - 60Years
MALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Healthy men aged 18 to 45 years for Part 1A and Part 2A
  • Willing and able to follow all study visits, treatments, tests, and procedures
  • Able to participate in Part 1B after Part 1A and follow all protocol requirements
  • Generally healthy with no disease needing medical treatment based on medical history, physical exam, vital signs, ECG, and lab tests at screening
  • For Japanese participants, parents and grandparents must be Japanese; for Caucasians in Part 2A, parents and grandparents must be Caucasian
  • For Part 1B, completed all visits after receiving PRD001 in Part 1A
  • Men aged 18 to 60 years for Part 2B
  • Generally healthy with no disease needing medical treatment (diet or exercise therapy allowed) based on medical history, physical exam, vital signs, ECG, and lab tests at screening
  • Parents and grandparents must be Japanese for Part 2B
  • Have mild hyper-LDL-cholesterolemia and mild hepatic steatosis
Not Eligible

You will not qualify if you...

  • Active, latent, or inadequately treated tuberculosis infection at screening
  • Positive QuantiFERON-TB Gold test or equivalent
  • Untreated, inadequately treated, or currently treated active tuberculosis infection
  • History of HIV infection, syphilis, hepatitis B, or hepatitis C at screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

SOUSEIKAI Fukuoka Mirai Hospital

Fukuoka, Fukuoka, Japan

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here